Advanced search
Publication Cover
Pharmacogenomics Volume 10, 2009 - Issue 9
Submit an article Journal homepage
168
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Effects of Genetic Variation at the CYP2C19/CYP2C9 Locus on Pharmacokinetics of Chlorcycloguanil in Adult Gambians

Ramatoulie E Janha1 Medical Research Council Laboratories, Fajara, PO Box  273, Banjul, The Gambia, West Africa Tel.: +220 44905442 Ext. 1804; Fax: +220 449 5919; [email protected]View further author information
,
Fatoumatta Sisay-Joof1 Medical Research Council Laboratories, Fajara, PO Box  273, Banjul, The Gambia, West Africa Tel.: +220 44905442 Ext. 1804; Fax: +220 449 5919; [email protected]View further author information
,
Majidah Hamid-Adiamoh1 Medical Research Council Laboratories, Fajara, PO Box  273, Banjul, The Gambia, West Africa Tel.: +220 44905442 Ext. 1804; Fax: +220 449 5919; [email protected]View further author information
,
Archibald Worwui1 Medical Research Council Laboratories, Fajara, PO Box  273, Banjul, The Gambia, West Africa Tel.: +220 44905442 Ext. 1804; Fax: +220 449 5919; [email protected]View further author information
,
Hannah L Chapman1 Medical Research Council Laboratories, Fajara, PO Box  273, Banjul, The Gambia, West Africa Tel.: +220 44905442 Ext. 1804; Fax: +220 449 5919; [email protected]View further author information
,
Hyginus Opara1 Medical Research Council Laboratories, Fajara, PO Box  273, Banjul, The Gambia, West Africa Tel.: +220 44905442 Ext. 1804; Fax: +220 449 5919; [email protected]View further author information
,
Sam Dunyo1 Medical Research Council Laboratories, Fajara, PO Box  273, Banjul, The Gambia, West Africa Tel.: +220 44905442 Ext. 1804; Fax: +220 449 5919; [email protected]View further author information
,
Paul Milligan2 London School of Hygiene and Tropical Medicine, London, UKView further author information
,
Kirk Rockett3 Wellcome Trust Centre for Human Genetics, Oxford, UKView further author information
,
Peter Winstanley4 University of Liverpool, UKView further author information
,
Munir Pirmohamed4 University of Liverpool, UKView further author information
,
Ann K Miller5 Clinical PK Modelling & Simulation, GlaxoSmithKline, PA, USAView further author information
,
David J Conway1 Medical Research Council Laboratories, Fajara, PO Box  273, Banjul, The Gambia, West Africa Tel.: +220 44905442 Ext. 1804; Fax: +220 449 5919; [email protected]View further author information
&
Robert T Walton1 Medical Research Council Laboratories, Fajara, PO Box  273, Banjul, The Gambia, West Africa Tel.: +220 44905442 Ext. 1804; Fax: +220 449 5919; [email protected];6 University of Oxford, Oxford, UKView further author information
 show all
Pages 1423-1431 | Published online: 17 Sep 2009

Bibliography

  • Evans WE , RellingMV: Pharmacogenomics: translating functional genomics into rational therapeutics.Science286 , 487–491 (1999).
  • Zanger UM , TurpeinenM, KleinK, SchwabM: Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation.Anal. Bioanal. Chem.392 , 1093–1108 (2008).
  • Sim SC , RisingerC, DahlML et al.: A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.Clin. Pharmacol. Ther.79 , 103–113 (2006).
  • WHO/HTM/GMP/2008.1: WHO World malaria report (2008).
  • Watkins WM , SixsmithDG, ChulayJD: The activity of proguanil and its metabolites, cycloguanil and p-chlorophenylbiguanide, against Plasmodium falciparumin vitro.Ann. Trop. Med. Parasitol.78 , 273–278 (1984).
  • Petersen E , FlachsH, HoghB, HansonAP, BjorkmanA, HvidbergEF: Plasma, erythrocyte and urine concentrations of chlorproguanil and two metabolites in man after different doses.J. Trop. Med. Hyg.94 , 199–205 (1991).
  • Wangboonskul J , WhiteNJ, NostenF, ter Kuile F, Moody RR, Taylor RB: Single dose pharmacokinetics of proguanil and its metabolites in pregnancy. Eur. J. Clin. Pharmacol.44 , 247–251 (1993).
  • Srivastava IK , VaidyaAB: A mechanism for the synergistic antimalarial action of atovaquone and proguanil.Antimicrob. Agents Chemother.43 , 1334–1339 (1999).
  • Stewart LB , PetersW, RobinsonBL: The chemotherapy of rodent malaria. LXII. Drug combinations to impede the selection of drug resistance, part 5: rates of development of resistance to some inhibitors of folate metabolism and to artesunate.Ann. Trop. Med. Parasitol.98 , 763–783 (2004).
  • Wright JD , HelsbyNA, WardSA: The role of S-mephenytoin hydroxylase (CYP2C19) in the metabolism of the antimalarial biguanides.Br. J. Clin. Pharmacol.39 , 441–444 (1995).
  • Chiluba EM , FletcherKA, PriceAH: The pharmacokinetics of proguanil in human subjects following a single oral dose.Afr. J. Med. Med. Sci.16 , 43–46 (1987).
  • Gill HJ , TingleMD, ParkBK: N-hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity.Br. J. Clin. Pharmacol.40 , 531–538 (1995).
  • Richardson A , Sisay-JoofF, AckermanH et al.: Nucleotide diversity of the TNF gene region in an African village.Genes Immun.2 , 343–348 (2001).
  • Stephens M , SmithNJ, DonnellyP: A new statistical method for haplotype reconstruction from population data.Am. J. Hum. Genet.68 , 978–989 (2001).
  • Herrlin K , MasseleAY, RimoyG et al.: Slow chloroguanide metabolism in Tanzanians compared with white subjects and Asian subjects confirms a decreased CYP2C19 activity in relation to genotype.Clin. Pharmacol. Ther.68 , 189–198 (2000).
  • Schroth W , AntoniadouL, FritzP et al.: Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.J. Clin. Oncol.25 , 5187–5193 (2007).
  • Blaisdell J , MohrenweiserH, JacksonJ et al.: Identification and functional characterization of new potentially defective alleles of human CYP2C19.Pharmacogenetics12 , 703–711 (2002).
  • Allabi AC , GalaJL, DesagerJP, HeusterspreuteM, HorsmansY: Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.Br. J. Clin. Pharmacol.56 , 653–657 (2003).
  • Lu AH , ShuY, HuangSL, WangW, Ou-YangDS, ZhouHH: In vitro proguanil activation to cycloguanil is mediated by CYP2C19 and CYP3A4 in adult Chinese liver microsomes.Acta Pharmacol. Sin.21 , 747–752 (2000).
  • Kaneko A , BergqvistY, TakechiM et al.: Intrinsic efficacy of proguanil against falciparum and vivax malaria independent of the metabolite cycloguanil.J. Infect. Dis.179 , 974–979 (1999).
  • Klotz U , SchwabM, TreiberG: CYP2C19 polymorphism and proton pump inhibitors.Basic Clin. Pharmacol. Toxicol.95 , 2–8 (2004).
  • Schwab M , SchaeffelerE, KlotzU, TreiberG: CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori.Clin. Pharmacol. Ther.76 , 201–209 (2004).

▪ Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.